Roivant Sciences Ltd. (NASDAQ:ROIV) Position Raised by Two Seas Capital LP

Two Seas Capital LP lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,167,807 shares of the company's stock after acquiring an additional 442,914 shares during the period. Roivant Sciences makes up approximately 9.5% of Two Seas Capital LP's portfolio, making the stock its 3rd biggest position. Two Seas Capital LP owned approximately 1.40% of Roivant Sciences worth $120,285,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. FMR LLC increased its stake in Roivant Sciences by 0.3% in the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock valued at $583,238,000 after purchasing an additional 156,527 shares in the last quarter. Vanguard Group Inc. increased its position in Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after buying an additional 2,404,232 shares in the last quarter. Invesco Ltd. raised its stake in Roivant Sciences by 49.7% during the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after buying an additional 3,159,603 shares during the period. Geode Capital Management LLC boosted its holdings in Roivant Sciences by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock worth $91,968,000 after acquiring an additional 26,727 shares in the last quarter. Finally, Norges Bank acquired a new stake in Roivant Sciences in the fourth quarter valued at approximately $52,443,000. 64.76% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ROIV. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st.

Insiders Place Their Bets

In related news, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00. Following the completion of the transaction, the chief operating officer now owns 896,869 shares of the company's stock, valued at approximately $9,551,654.85. This represents a 10.03 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,395,541 shares of company stock valued at $14,922,538. Corporate insiders own 7.90% of the company's stock.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded up $0.24 on Wednesday, hitting $11.53. The company had a trading volume of 2,618,802 shares, compared to its average volume of 5,463,554. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The stock has a 50 day moving average of $10.36 and a 200-day moving average of $11.14. The stock has a market capitalization of $8.23 billion, a price-to-earnings ratio of -76.86 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.